

# Review of: "Efficacy of Potassium Competitive Acid Blockers (P-CABs) versus Proton Pump Inhibitors (PPIs) in the First and Second Line Eradication Regimens for *Helicobacter pylori* in Egyptian Patients"

Mitsushige Sugimoto<sup>1</sup>

<sup>1</sup> Tokyo Medical College

Potential competing interests: No potential competing interests to declare.

## General:

Authors investigated to compare the efficacy of vonoprazan-based eradication therapy and PPI-based therapy for *H. pylori* infection in Egyptian patients. However, authors failed to show efficacy of vonoprazan-based therapy in Egyptian patients.

## Comments:

1. In meta-analyses of Asian trials, the triple combination of vonoprazan, amoxicillin, and clarithromycin was associated with significantly higher eradication rates than PPI-based triple therapy. Why did authors fail in this study?
2. In Japanese study, eradication rates in first-line and second-line vonoprazan-based regimens were around 85-95 and 80-95%, respectively. Why was the eradication rate less than 70% in all four arms? Authors should mention in Discussion section.
3. This study is prospective, non-randomized study. How did authors select regimen?
4. Please show how to determine sample size in this study.
5. Good compliance was defined as drug consumption >75% of the total dosage. Is it enough to analyze?
6. Please add body weight, height, history of GERD, peptic ulcer, and gastric cancer, history taking PPI or H2RA in Table 1.
7. Serious problem of this study is loss of data about susceptibility to antimicrobial agents.